Technical Analysis for BHVN - Biohaven Pharmaceutical Holding Company Ltd.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Up |
| Historical BHVN trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Crossed Above 20 DMA | Bullish | 0.00% | |
| Pocket Pivot | Bullish Swing Setup | 0.00% | |
| Lower Bollinger Band Walk | Weakness | 0.00% | |
| Multiple of Ten Bullish | Other | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Lower Bollinger Band Walk | Weakness | 7.91% | |
| Multiple of Ten Bearish | Other | 7.91% | |
| Down 3 Days in a Row | Weakness | 7.91% | |
| Lower Bollinger Band Touch | Weakness | 7.91% | |
| MACD Bearish Signal Line Cross | Bearish | 6.03% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time | |
|---|---|---|
| Possible Pocket Pivot | about 5 hours ago | |
| 20 DMA Resistance | about 7 hours ago | |
| Rose Above 20 DMA | about 7 hours ago | |
| 10 DMA Resistance | about 9 hours ago | |
| Rose Above 10 DMA | about 9 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 03/01/2021
Biohaven Pharmaceutical Holding Company Ltd. Description
Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates. Its pipeline includes BHV-0223, which is a formulation of a glutamate-modulating agent; BHV-4157, which is a new chemical entity (NCE) that modulates glutamate, and BHV-5000, which is an in-licensed investigational agent of the Company targeting N-Methyl-D-Aspartate (NMDA) receptor antagonism. Its clinical compound, trigriluzole, is indicated for neurodegenerative diseases and cancer indications, among others. Its pipeline also includes BHV-3000 and BHV-3500, which are in-licensed by the Company for a neurologic indication. It focuses on advancing other mechanistic approaches in orphan and neuroscience indications, and is exploring licenses for additional compounds.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Drugs Chemical Compounds Organic Compounds Neuroscience Degenerative Disease Degenerative Diseases Neurodegenerative Diseases Glutamate Chemical Entity Riluzole
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 100.77 |
| 52 Week Low | 26.56 |
| Average Volume | 520,340 |
| 200-Day Moving Average | 75.82 |
| 50-Day Moving Average | 84.78 |
| 20-Day Moving Average | 83.60 |
| 10-Day Moving Average | 82.36 |
| Average True Range | 4.68 |
| ADX | 12.97 |
| +DI | 19.31 |
| -DI | 22.82 |
| Chandelier Exit (Long, 3 ATRs ) | 75.73 |
| Chandelier Exit (Short, 3 ATRs ) | 89.91 |
| Upper Bollinger Band | 89.56 |
| Lower Bollinger Band | 77.65 |
| Percent B (%b) | 0.54 |
| BandWidth | 14.25 |
| MACD Line | -0.94 |
| MACD Signal Line | -0.81 |
| MACD Histogram | -0.1271 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 94.62 | ||||
| Resistance 3 (R3) | 93.52 | 88.88 | 92.86 | ||
| Resistance 2 (R2) | 88.88 | 86.18 | 89.43 | 92.27 | |
| Resistance 1 (R1) | 86.46 | 84.52 | 87.67 | 87.56 | 91.68 |
| Pivot Point | 81.82 | 81.82 | 82.42 | 82.37 | 81.82 |
| Support 1 (S1) | 79.39 | 79.12 | 80.61 | 80.50 | 76.38 |
| Support 2 (S2) | 74.76 | 77.45 | 75.31 | 75.79 | |
| Support 3 (S3) | 72.33 | 74.76 | 75.20 | ||
| Support 4 (S4) | 73.44 |
